Fc&ggr; Receptor Polymorphisms Do Not Predict Response to Intravenous Immunoglobulin in Myasthenia Gravis

Abstract We studied 63 patients with myasthenia gravis (MG) requiring treatment with intravenous immunoglobulin, to determine if polymorphisms within the FC&ggr;R2A (rs1801274), FC&ggr;R2B (rs1050501), FC&ggr;R3A (rs396991), and FC&ggr;R3B (NA1/NA2) genes are correlated with response to treatment. There was no significant difference in any of the polymorphisms studied between responders and nonresponders. Patients with the FC&ggr;R2B-232I/I polymorphism had higher disease severity measured by the quatitative myasthenia gravis score (QMGS). There was no difference in the distribution of the FC&ggr;R2B-232 polymorphisms between the patients and 90 healthy controls. The finding of greater disease severity in patients with the FC&ggr;R2B-232I/I polymorphism requires confirmation in a larger population of patients with myasthenia gravis.

[1]  V. Bril,et al.  Comparison of IVIg and PLEX in patients with myasthenia gravis , 2011, Neurology.

[2]  T. Takeuchi,et al.  Extended Report , 2022 .

[3]  Kenneth G. C. Smith,et al.  FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications , 2010, Nature Reviews Immunology.

[4]  Wei Zhang,et al.  Fcγ receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma , 2010 .

[5]  Wei Zhang,et al.  Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma. , 2010, Chinese medical journal.

[6]  S. Miescher,et al.  Intravenous immunoglobulins – understanding properties and mechanisms , 2009, Clinical and experimental immunology.

[7]  W. Oertel,et al.  Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy , 2009, Proceedings of the National Academy of Sciences.

[8]  H. Hartung,et al.  Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial , 2008, The Lancet Neurology.

[9]  L. Zinman,et al.  IV immunoglobulin in patients with myasthenia gravis , 2007, Neurology.

[10]  S. Higgs,et al.  Genetic evidence for the involvement of Fcγ receptor III in experimental autoimmune myasthenia gravis pathogenesis , 2006, Journal of Neuroimmunology.

[11]  Y. Komiyama,et al.  Polymorphism of Fcγ RIIa May Affect the Efficacy of γ-Globulin Therapy in Kawasaki Disease , 2005, Journal of Clinical Immunology.

[12]  J. Odeberg,et al.  Polymorphisms of the Fc gamma receptor type IIB gene are not associated with systemic lupus erythematosus in the Swedish population. , 2004, Arthritis and rheumatism.

[13]  J. Kuks,et al.  Association of the Fcγ receptor IIA-R/R131 genotype with myasthenia gravis in Dutch patients , 2003, Journal of Neuroimmunology.

[14]  R. Geha,et al.  IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy. , 2003, The Journal of allergy and clinical immunology.

[15]  S. Chevret,et al.  Intravenous immunoglobulin for myasthenia gravis. , 2003, The Cochrane database of systematic reviews.

[16]  Pak Chung Sham,et al.  Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits , 2003, Bioinform..

[17]  S. Chevret,et al.  Plasma exchange for myasthenia gravis. , 2002, The Cochrane database of systematic reviews.

[18]  D. Sanders.  Myasthenia gravis and myasthenic disorders , 2000 .

[19]  J. G. Winkel,et al.  IgG receptor polymorphisms: risk factors for disease , 1998, Immunogenetics.

[20]  N. Gilhus,et al.  FcγRIIA and FcγRIIIB polymorphisms in myasthenia gravis , 1998, Journal of Neuroimmunology.

[21]  J. V. D. van de Winkel,et al.  IgG receptor polymorphisms: risk factors for disease , 1998, Immunogenetics.

[22]  W. Fridman,et al.  Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura , 1993, The Lancet.

[23]  W. Fridman,et al.  Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. , 1993, Lancet.

[24]  S. Burdach,et al.  Treatment of acute idiopathic thrombocytopenic purpura of childhood with intravenous immunoglobulin G: comparative efficacy of 7S and 5S preparations. , 1986, The Journal of pediatrics.